AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Friday.
Other analysts have also recently issued reports about the stock. Jefferies Group LLC reiterated a “buy” rating and issued a $7.00 target price on shares of AcelRx Pharmaceuticals in a research note on Friday, July 14th. Roth Capital set a $13.00 target price on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. Royal Bank Of Canada set a $6.00 target price on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 25th. Stifel Nicolaus upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of AcelRx Pharmaceuticals in a research note on Friday, August 4th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the stock. AcelRx Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $7.50.
Shares of AcelRx Pharmaceuticals (NASDAQ ACRX) traded up 3.33% on Friday, reaching $3.10. 1,116,705 shares of the company’s stock traded hands. The company’s 50-day moving average price is $3.12 and its 200 day moving average price is $2.81. AcelRx Pharmaceuticals has a one year low of $1.95 and a one year high of $4.08. The firm’s market cap is $140.68 million.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.01). AcelRx Pharmaceuticals had a negative return on equity of 478.66% and a negative net margin of 319.19%. The firm had revenue of $2.66 million during the quarter, compared to analysts’ expectations of $2.63 million. On average, equities analysts forecast that AcelRx Pharmaceuticals will post ($1.13) EPS for the current fiscal year.
In related news, insider Pamela P. Palmer acquired 10,000 shares of the stock in a transaction dated Tuesday, August 22nd. The shares were purchased at an average price of $2.95 per share, for a total transaction of $29,500.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of the firm’s stock in a transaction on Monday, June 19th. The shares were sold at an average price of $2.40, for a total transaction of $2,100,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have bought 37,000 shares of company stock worth $112,280. Corporate insiders own 28.10% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. purchased a new stake in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at $530,000. Virtu KCG Holdings LLC raised its position in shares of AcelRx Pharmaceuticals by 600.9% during the 2nd quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after buying an additional 101,742 shares in the last quarter. LMR Partners LLP purchased a new stake in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at $319,000. WealthTrust Axiom LLC raised its position in shares of AcelRx Pharmaceuticals by 50.0% during the 2nd quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock valued at $451,000 after buying an additional 70,000 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of AcelRx Pharmaceuticals by 6.6% during the 1st quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock valued at $355,000 after buying an additional 6,942 shares in the last quarter. Hedge funds and other institutional investors own 23.32% of the company’s stock.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.